Published on 20 Apr 2022 on Insider Monkey via Yahoo Finance

Analysts Are Downgrading These 10 Pharmaceutical Stocks

In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks.

The pharmaceutical industry always remains in focus as investors scramble to find innovative companies working on treatments of diseases. The COVID-19 pandemic further highlighted the importance of biotech and pharmaceutical industries. According to a report by Deloitte, since 2020, the proportion of late-stage pipelines focused on infectious disease assets has grown by 4%. However, the enthusiasm around biotech and pharma stocks seen immediately after the pandemic is slowing down. The SPDR S&P Biotech ETF was down close to 20% in the first quarter of 2022, as compared to a 5% decline for the S&P 500. Still, analysts believe that notable pharmaceutical and biotech stocks like Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) have long-term growth potential because of their strong pipelines and massive R&D budgets.